Publications

2023

Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity.
Houlahan KE, Khan A, Greenwald NF, West RB, Angelo M, Curtis C. bioRxiv. 2023 Mar 16:2023.03.15.532870. doi: 10.1101/2023.03.15.532870. Preprint.PMID: 36993286

A microwell platform for high-throughput longitudinal phenotyping and selective retrieval of organoids.
Sockell A, Wong W, Longwell S, Vu T, Karlsson K, Mokhtari D, Schaepe J, Lo YH, Cornelius V, Kuo C, Van Valen D, Curtis C, Fordyce PM. Cell Syst. 2023 Sep 20;14(9):764-776.e6. doi: 10.1016/j.cels.2023.08.002.PMID: 37734323

Deterministic evolution and stringent selection during pre-neoplasia.
Karlsson K, Przybilla M, Kotler E, Khan A, Xu H, Karagyozova K, Sockell A, Wong WH, Liu K, Mah A, Lo YH, Lu B, Houlahan KE, , Ma Z, Suarez CJ, Barnes CP, Kuo CJ, Curtis C. Nature 18(7964):383-393. doi: 10.1038/s41586-023-06102-8. PMID: 37258665

PhyloVelo enhances transcriptomic velocity field mapping using monotonically expressed genes
Kun Wang, Liangzhen Hou, Xin Wang, Xiangwei Zhai, Zhaolian Lu, Zhike Zi, Weiwei Zhai, Xionglei He, Christina Curtis, Da Zhou, Zheng Hu. 2023 Jul 31. PMID: 37524958 DOI: 10.1038/s41587-023-01887-5

Development and characterization of new patient-derived xenograft (PDX) models of osteosarcoma with distinct metastatic capacities. 
Schott CR, Koehne AL, Sayles LC, Young EP, Luck C, Yu K, Lee AG, Breese MR, Leung SG, Xu H, Shah AT, Liu HY, Spillinger A, Behroozfard IH, Marini KD, Dinh PT, Pons Ventura MAV, Vanderboon EN, Hazard FK, Cho SJ, Avedian RS, Mohler DG, Zimel M, Wustrack R, Curtis C, Sirota M, Sweet-Cordero EA.bioRxiv. 2023 Jan 20:2023.01.19.524562. doi: 10.1101/2023.01.19.524562. Preprint. PMID: 36711882

Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach. 
Schott CR, Koehne AL, Sayles LC, Young EP, Luck C, Yu K, Lee AG, Breese MR, Leung SG, Xu H, Shah AT, Liu HY, Spillinger A, Behroozfard IH, Marini KD, Dinh PT, Pons Ventura MV, Vanderboon EN, Hazard FK, Cho SJ, Avedian RS, Mohler DG, Zimel M, Wustrack R, Curtis C, Sirota M, Sweet-Cordero EA.Clin Cancer Res. 2023 Sep 13:OF1-OF16. doi: 10.1158/1078-0432.CCR-23-0873. Online ahead of print. PMID: 37703185

Serine starvation silences estrogen receptor signaling through histone hypoacetylation. 
Li AM, He B, Karagiannis D, Li Y, Jiang H, Srinivasan P, Ramirez Y, Zhou MN, Curtis C, Gruber JJ, Lu C, Rankin EB, Ye J. Proc Natl Acad Sci U S A. 2023 Sep 19;120(38):e2302489120. doi: 10.1073/pnas.2302489120. Epub 2023 Sep 11.PMID: 37695911

2022

Engineered extracellular matrices reveal stiffness-mediated chemoresistance in patient derived pancreatic cancer organoids.
LeSavage BL, Gilchrist AE , Krajina BA, Karlsson K, Smith AR , Karagyozova K , Klett KC , Curtis C, Kuo CJ, Heilshorn SJ. Biorxiv. doi: 10.1101/2022.04.22.488943v1.

Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer.   
Becker WR, Nevins SA, Chen DC, Chiu R, Horning AM, Guha TK, Laquindanum R, Mills M, Chaib H, Ladabaum U, Longacre T, Shen J, Esplin ED, Kundaje A, Ford JM, Curtis C, Snyder MP, Greenleaf WJ. Nat Genet. 2022 Jul;54(7):985-995. doi: 10.1038/s41588-022-01088-x. Epub 2022 Jun 20. PMID: 35726067 

Targeted profiling of human extrachromosomal DNA by CRISPR-CATCH.
Hung KL, Luebeck J, Dehkordi SR, Colón CI, Li R, Wong IT, Coruh C, Dharanipragada P, Lomeli SH, Weiser NE, Moriceau G, Zhang X, Bailey C, Houlahan KE, Yang W, González RC, Swanton C, Curtis C, Jamal-Hanjani M, Henssen AG, Law JA, Greenleaf WJ, Lo RS, Mischel PS, Bafna V, Chang HY.   Nat Genet. 2022 Nov;54(11):1746-1754. doi: 10.1038/s41588-022-01190-0. Epub 2022. PMID: 36253572 

Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.
Strand, S. H., Rivero-Gutierrez, B., Houlahan, K. E., Seoane, J. A., King, L. M., Risom, T., Simpson, L. A., Vennam, S., Khan, A., Cisneros, L., Hardman, T., Harmon, B., Couch, F., Gallagher, K., Kilgore, M., Wei, S., DeMichele, A., King, T., McAuliffe, P. F., Nangia, J., Lee, J., Tseng, J., Storniolo, A. M., Thompson, A. M., Gupta, G. P., Burns, R., Veis, D. J., DeSchryver, K., Zhu, C., Matusiak, M., Wang, J., Zhu, S. X., Tappenden, J., Ding, D. Y., Zhang, D., Luo, J., Jiang, S., Varma, S., Anderson, L., Straub, C., Srivastava, S., Curtis, C., Tibshirani, R., Angelo, R. M., Hall, A., Owzar, K., Polyak, K., Maley, C., Marks, J. R., Colditz, G. A., Hwang, E. S., West, R. B. Cancer Cell S1535-6108(22)00512-8. doi: 10.1016/j.ccell.2022.10.021. 2022

ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung.
Nobre AR, Dalla E, Yang J, Huang X, Wullkopf L, Risson E, Razghandi P, Anton ML, Zheng W, Seoane JA, Curtis C, Kenigsberg E, Wang J, Aguirre-Ghiso JA. Nat Cancer. 2022 Oct;3(10):1165-1180. doi: 10.1038/s43018-022-00424-8. PMID: 36050483

Most cancers carry a substantial deleterious load due to Hill-Robertson interference.
Tilk S, Tkachenko S, Curtis C, Petrov DA, McFarland CD. Elife. 2022 Sep 1;11:e67790. doi: 10.7554/eLife.67790. PMID: 36047771

"Fateful" encounter: Lineage tracing meets phylogeny to unravel mysteries of cancer progression. 
Wong WH, Curtis C. Dev Cell. 2022 Jul 25;57(14):1680-1682. doi: 10.1016/j.devcel.2022.07.002. PMID: 35901781

Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Esserman LJ, van 't Veer LJ, Rugo HS, Curtis C, Klefström J, Matloubian M, Goga A.Nat Commun. 2022 Jun 27;13(1):3671. doi: 10.1038/s41467-022-31238-y. PMID: 35760778 

Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.
Parikh DA, Kody L, Brain S, Heditsian D, Lee V, Curtis C, Karin MR, Wapnir IL, Patel MI, Sledge GW Jr, Caswell-Jin JL. Breast Cancer Res Treat. 2022 Jul;194(1):171-178. doi: 10.1007/s10549-022-06611-6. Epub 2022 May 11.
PMID: 35538268 

The Mettl3 epitranscriptomic writer amplifies p53 stress responses.
Raj N, Wang M, Seoane JA, Zhao RL, Kaiser AM, Moonie NA, Demeter J, Boutelle AM, Kerr CH, Mulligan AS, Moffatt C, Zeng SX, Lu H, Barna M, Curtis C, Chang HY, Jackson PK, Attardi LD. Mol Cell. 2022 Jul 7;82(13):2370-2384.e10. doi: 10.1016/j.molcel.2022.04.010. Epub 2022 May 4.
PMID: 35512709

MITI minimum information guidelines for highly multiplexed tissue images.
Schapiro D, Yapp C, Sokolov A, Reynolds SM, Chen YA, Sudar D, Xie Y, Muhlich J, Arias-Camison R, Arena S, Taylor AJ, Nikolov M, Tyler M, Lin JR, Burlingame EA; Human Tumor Atlas Network, Chang YH, Farhi SL, Thorsson V, Venkatamohan N, Drewes JL, Pe'er D, Gutman DA, Herrmann MD, Gehlenborg N, Bankhead P, Roland JT, Herndon JM, Snyder MP, Angelo M, Nolan G, Swedlow JR, Schultz N, Merrick DT, Mazzili SA, Cerami E, Rodig SJ, Santagata S, Sorger PK. Nat Methods. 2022 Mar;19(3):262-267. doi: 10.1038/s41592-022-01415-4.
PMID: 35277708 

2021

Pan-cancer organoid validation of tumor outlier chromosomal amplification
Salahudeen AA, Yuki K, Seoane JA, Mah AT, Smith AR, Kolahi K, De la O SM, Hart DJ, Ding J, Ma Z, Barkal S, Navika D. Shukla, Zhang Z, Cantrell MA, Batish A, Usui T, Root D, Hahn W, Curtis C, Kuo CJ.  events. Biorxiv. doi:10.1101/2021.10.05.463147.

Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. 
McNamara K, Caswell-Jin JL, Ma Z, Joshi R, Kotler E, Bean G, Kriner M, Zhou Z, Hoang M, Beechem J, Zoeller J, Press MF, Slamon D, Hurvitz S & Curtis C. Nature Cancer. doi:10.1038/s43018-021-00190-z, 2021.

Molecular heterogeneity and evolution in breast cancer.
Caswell-Jin JL, Lorenz C, Curtis C.  Annual Reviews in Cancer Biology (5) 2021. doi:10.1146/annurev-cancerbio-060220-014137.

A high-dimensional window into the microenvironment of triple negative breast cancer. 
Nederof I, Horlings HM, Curtis C, Kok M. Cancers (Basel) 13(2): E16. doi:10.3390/cancers13020316. PMID: 33467084.

A CRISPR/Cas9-engineered ARID1A-deficient human gastric cancer organoid model reveals essential and non-essential modes of oncogenic transformation.
Lo YH, Kolahi KS, Du Y, Chang CY, Krokhotin A, Nair A, Sobba WD, Karlsson K, Jones SJ, Longacre TA, Mah AT, Tercan B, Sockell A, Xu H, Seoane JA, Chen J, Shmulevich I, Weissman JS, Curtis C, Califano A, Fu H, Crabtree GR, Kuo CJ.Cancer Discovery, 2021 Jan 15;candisc.1109.2020. doi:10.1158/2159-8290.CD-20-1109.

Androgen receptor agonists as breast cancer therapeutics.
Caswell-Jin JL and Curtis C. Nature Medicine, 2021. doi:10.1038/s41591-021-01242-8.

A CRISPR/Cas9-engineered ARID1A-deficient human gastric cancer organoid model reveals essential and non-essential modes of oncogenic transformation.
Lo YH, Kolahi KS, Du Y, Chang CY, Krokhotin A, Nair A, Sobba WD, Karlsson K, Jones SJ, Longacre TA, Mah AT, Tercan B, Sockell A, Xu H, Seoane JA, Chen J, Shmulevich I, Weissman JS, Curtis C, Califano A, Fu H, Crabtree GR, Kuo CJ.Cancer Discovery, 2021 Jan 15;candisc.1109.2020. doi:10.1158/2159-8290.CD-20-1109.

2020

Hurvitz S, Caswell-Jin J, McNamara K, Zoeller J, Bean G,  Dichmann R, Perez A, Patel R, Zehngebot L, Allen H, Bosserman L, DiCarlo B, Kennedy A, Giuliano A, Calfa C, Molthrop D, Mani A, Chen HW, Dering J, Adams B, Press M, Brugge J, Curts C†, Slamon D†. Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nature Communications, 2020. doi:10.1038/s41467-020-19494-2.

Caswell-Jin JL, Lorenz C, Curtis C. Molecular heterogeneity and evolution in breast cancer. Annual Reviews in Cancer Biology, 2020;5. doi:10.1146/annurev-cancerbio-060220-014137.

Bieging-Rolett KT, Kaiser AM, Morgens DW, Boutelle AM, Seoane JA, Van Nostrand EL, Zhu C, Houlihan SL, Mello SS, Yee BA, McClendon J, Pierce SE, Winters IP, Wang M, Connolly AJ, Lowe SW, Curtis C, Yeo GW, Winslow MM, Bassik MC, Attardi LD. Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program. Mol Cell., 2020 Nov 5;80(3):452-469.e9. doi:10.1016/j.molcel.2020.10.022.

Nasa Sinnott-Armstrong, Jose A Seoane, Jonathan K Pritchard,  Christina Curtis, Michael P Snyder. Convergent mutations in tissue-specific regulatory regions reveal novel cancer drivers. Biorxiv. doi:10.1101/2020.08.21.239954.

Zahir N, Sun R, Gallahan D, Gatenby RA, Curtis C. Characterizing the ecological and evolutionary dynamics of cancer. Nat Genet., 2020 Aug;52(8):759-767. doi:10.1038/s41588-020-0668-4. Epub 2020 Jul 27.

Hu Z, Curtis C. Looking backward in time to define the chronology of metastasis. Nat Commun., 2020 Jun 25;11(1):3213. doi:10.1038/s41467-020-16995-y.

Xiao Y, Thakkar KN, Zhao H, Broughton J, Li Y, Seoane JA, Diep AN, Metzner TJ, von Eyben R, Dill DL, Brooks JD, Curtis C, Leppert JT, Ye J, Peehl DM, Giaccia AJ, Sinha S, Rankin EB. The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor. Proc Natl Acad Sci U S A, 2020 Aug 19:202000516. doi:10.1073/pnas.2000516117.

Hu Z, Li Z, Ma Z, Curtis C. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nature Genetics. doi:10.1038/s41588-020-0628-z, 2020.

Baslan T, Kendall J, Volyanskyy K, McNamara K, Cox H, D’Italia S, Ambrosio F, Riggs M, Rodgers L, Leotta A, Song J , Mao Y, Shah R, Merida RG , Chadalavada K , Gouri Nanjangud, Vinay Varadan , Gordon A, Curtis C,  Krasnitz A , Dimitrova N, Harris L, Wigler M  & Hicks J. Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing. ELife e51480. doi:10.7554/eLife.51480, 2020.

Tilk S, Curtis C, Petrov D, McFarland C. Most cancers carry a substantial deleterious load due to Hill-Robertson interference. Biorxiv. doi:10.1101/764340v2.

Curtis C. Quantifying mutations in healthy blood. Science. doi:10.1126/science.aba989, 2020.

Han K, Pierce S, Li A, Spees K, Anderson G, Seoane JA, Wainberg M, Kostyrko K, Kelly M, Yousefi M, Simpkins S, Yao D, Lee K, Kuo C, Shokat K, Jackson P, Sweet-Cordero A, Kundaje A, Gentles A, Curtis C, Winslow MM, Bassik M.  Genome-wide CRISPR screens in lung cancer spheroids identify 3D growth specific cancer vulnerabilities. Nature. doi:10.1038/s41586-020-2099-x, 2020.

Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV on behalf of the CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Annals of Oncology. doi:10.1016/j.annonc.2020.02.011, 2020.

Mao A, Ducker GS, Li Y, Seoane JA, Zhou Y, Liu L, Vanharanta S, Rankin EB, Massagué J, Curtis C, Rabinowitz R, Thompson CB, Ye J. Metabolic Profiling Reveals a Dependency of Human Metastatic Breast Cancer on Serine and One-Carbon Unit Metabolism. Molecular Cancer Research. doi:10.1158/1541-7786.MCR-19-0606, 2020.

2019

Seoane JA, Kirkland GR, Caswell-Jin J, Crabtree GR & Curtis C. Chromatin regulators mediate anthracycline sensitivity in breast cancer. Nature Medicine doi:10.1038/s41591-019-0638-5, 2019

Press releases:
Forbes Medicine
Stanford news
ocg.cancer.gov

Hu Z, Ding J, Ma Z, Sun R, Seoane JA, Suarez CJ, Shaffer S, Berghoff AS, Cremolini C, Falcone A, Loupakis, Birner P, Preusser M, Lenz HJ & Curtis C. Quantitative evidence for early metastatic seeding in colorectal cancer. Nature Genetics doi:10.1038/s41588-019-0423-x, 2019.

On the cover

Press releases:
Forbes Medicine
Medscape Medical News

Commentary in Cancer Discovery: Seeds of Metastatic Colorectal Cancer are Planted Early in Disease Progression doi: 10.1158/2159-8290.CD-RW2019-097.

Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, McNamara K, Granja JM, Sarin KY, Brown RA, Gupta RK, Curtis C, Bucktrout S, Davis MM, Chang ALS, Chang HY. Clonal replacement of tumor-specific T cells following PD-1 blockade.  Nature Medicine doi:10.1038.

Rueda OM, Sammut SJ, Seoane JA, Chin SF, Caswell-Jin J, Ali R, Pereira B, Batra R, Bruna A, Callari M, Provenzano E, Liu B, Wright K, Parisien P, Gillett C, McKinney S, Green AR, Murphy L, Purushotham A, Ellis IO, Pharoah PD, Rueda R, Aparicio S, Caldas C & Curtis C. The dynamics of breast cancer relapse reveal late-recurring ER+ genomic subgroups. Nature doi:10.1038/s41586-019-1007-8, 2019.

Press releases:
Stanford Medicine
Yahoo News
Forbes Medicine

Caswell-Jin JL, McNamara K, Reiter JG, Sun R, Hu Z, Ma Z, Ding J, Suarez CJ, Tilk S, Raghavendra A, Forte V, Chin SF, Bardwell H, Provenzano E, Caldas C, Lang J, West R, Tripathy D, Press MF, Curtis C. Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy. Nature Communications 10(1):657, 2019.

2018

Corces MR, Granja JM, Shams S, Louie BH, Seoane JA, Zhou W, Silva TC, Groeneveld C, Wong CK, Cho SW, Satpathy AT, Mumbach MR, Hoadley KA, Robertson AG, Sheffield NC, Felau I, Castro MAA, Berman BP, Staudt LM, Zenklusen JC, Laird PW, Curtis C; Cancer Genome Atlas Analysis Network, Greenleaf W & Chang HJ. The Chromatin Accessibility Landscape of Primary Human Cancers. Science 362(6413) 2018.

Press MF, Seoane JA, Curtis C, Guzman R, Quinaux E, Sauter G, Eiermann W, Mackey JR, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Bee V, Ma Y, Villalobos I, & Slamon DJ. Assessment of HER2 / ERBB2 Status in “HER2 Equivocal” Breast Cancers and the ASCO-CAP Guidelines:  False-Positives due to Heterozygous Deletions of Alternative Control Loci. JAMA Oncology JAMA Oncoldoi: 10.1001/jamaoncol.2018.6012 2018.

Probert C, Curtis C. A role for chromatin regulatory dynamics in breast cancer evolution. Nature Medicine, News & Views. 24(9):1309-1311, 2018.

Bhatt AS, Curtis C. AGBT meeting report. Genome Biol. 2018 May 21;19(1):60. doi: 10.1186/s13059-018-1447-8.

Pogrebniak K & Curtis C. Harnessing tumor evolution to circumvent resistance. Trends In Genetics, in press.

Calvin Kuo & Curtis C. Organoids reveal cancer dynamics. Nature, News & Views. 556(7702):441-442, 2018.

Afghahi A, Purington N, Han S, Desai M, Pierson E, Mathur M, Seto T, Thompson C, Rigdon J, Telli M, Badve S, Curtis C, West R, Horst K, Gomez G, Ford J, Sledge G & Kurian A. Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research, pii: clincanres.1323.2017. doi: 10.1158/1078-0432.CCR-17-1323, 2018.

Rogers ZN, McFarland CD, Winters IP, Seoane JA, Brady JJ, Curtis C, Petrov D & Winslow MM. The fitness landscape of tumor suppression in lung adenocarcinoma in vivo. Nature Genetics 2018 doi:10.1038/s41588-018-0083-2.

Williams MK, Werner B, Curtis C, Barnes CP, Sottoriva S & Graham TA. Quantification of subclonal selection in cancer from bulk sequencing data. Nature Genetics, 50(6);895-903 2018.

Cho S, Xu J, Sun R, Mumbach M, Carter AC, Chen YG, Yost KE, Kim J, Nevins S, Chin SF, Carlos Caldas C, Liu JS, Horbeck M, Lim DA, Weissman JS, Curtis C & Chang HY. Promoter of lncRNA gene PVT1 is a tumor suppressor DNA boundary element. Cell, 31;173(6):1398-1412.e22, 2018.

2017

Mello SS, Valente LJ, Raj N, Seoane JA, ... , Curtis C, Attardi LD. A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. Cancer Cell. 32(4):460-473.e6 2017.

Sun R, Hu Z, Curtis, C. Big Bang tumor dynamics and clonal evolution. In Cancer Evolution. Cold Spring Harbor Perspect Med, Cold Spring Harbor Press. pii: a028381 2017. doi: 10.1101, 2017.

Yan KS, Gevaert O, Zheng GX, Anchang B, Probert CS, ... , Curtis C, Ji HP, Li L, Henning SK, Wong MH & Kuo CJ. Mature enteroendocrine cells possess injury-inducible reserve stem cell function. Cell Stem Cell, 6;21(1):78-90.e6, 2017.

Sun R, Hu Z, Sottoriva A, Graham TA, Harpak A, Ma Z, Shibata D & Curtis C. Between-region genetic divergence reflects the mode and tempo of tumor evolution. Nature Genetics, 2017 doi: 10.1038/ng.3891.

Hu Z, Sun R & Curtis, C. A Population Genetic Perspective on Tumor Evolution. Evolutionary principles – heterogeneity in cancer. Biochimica et Biophysica Acta - Reviews on Cancer, pii: S0304-419X(17)30046-X. doi: 10.1016/j.bbcan.2017.03.001, 2017.

Zhao J, Salomon MP, Shibata D, Curtis C, Siegmund K & Marjoram P. Early mutation bursts and cancer stem cell division asymmetry in colorectal tumors. PLoS One, 12(3):e0172516, 2017.

TCGA Research Atlas Network, Seoane JA…Curtis, C...  Integrated genomic characterization of oesophageal carcinoma. Nature Jan, 2017 doi: 10.1038/nature20805.

Gendelman R, Xing H, Mirzoeva OK, Sarde P, Curtis C, Feiler HS, McDonagh P, Gray JW, Khalil I, & Korn MW.. Bayesian network inference modeling identifies TRIB1 as a novel regulator of cell cycle progression and survival in cancer cells. Cancer Research, 2017.

2016

Hu Z, Curtis C. Inferring tumor phylogenies from multi-region sequencing. Cell Syst. 3(1):12-4, 2016. 

Hu Z, Mao JH, Curtis C, Huang G, Kuo WL, Lenburg ME, Gu S, Korkola JE, Ziyad S, Bayani N, Samarajiwa S, Seoane JA, Dan M, Esch A, Feiler HS, Wang NJ, Hardwicke MA, Laquerre S, Jackson J, Wood K, Weber B, Spellman PT, Aparicio S, Wooster R, Caldas C, & Gray JW. Genomic co-amplification up-regulates a mitotic gene network whose activity predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Research, 18(1):70, 2016. 

2015

Kang H, Salomon MP, Sottoriva A, Zhao J, Toy M, Press MF, Curtis C, Marjoram P, Siegmund K, Shibata D. Many private mutations originate from the first few divisions of a human colorectal adenoma. J Pathology, 2015.    

Sottoriva A, Kang H, Ma Z, Graham TA, Salomon M, Zhao J, Marjoram P, Siegmund K, Press MF, Shibata D & Curtis C. A Big Bang Model of human colorectal tumor growth. Nature Genetics, 2015.

** Recommended by Faculty of 1000 Prime

- Nature Genetics News and Views Commentary: Big Bang and Context Driven Collapse

- Nature Reviews Cancer Research Highlight: Explosive Beginnings

Curtis C. Genomic Profiling of breast cancers. Curr Opin Obstet Gynecol, 27(1), 2015.

Piccirillo SGM, Spiteri I, Sottoriva A, Touloumis A, Ber S, Price SJ, Heywood R, Francis NJ, Collins VP, Venkitaraman AR, Curtis C, Marioni JC, Tavaré S & Watts C. Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone. Cancer Res 75(1), 2015. 

Moen Vollan HK, Rueda OM, Chin SF, Curtis C, Turashvili G, Shah SP, Lingjaerde OC, Yuan Y, Ng CK, Dunning MJ, Dicks E, Provenzano E, Sammut S, McKinney S, Ellis IO, Pinder S, Purushotham A, Murphy LC, METABRIC Group, Tavaré S, Brenton JD, Pharoah PD, Børrensen-Dale AL, Aparicio S & Caldas C. A tumor DNA complex-arm aberration index is an independent predictor of survival in breast and ovarian cancer. Molecular Oncology, 9(1), 2015. 

2014

Ali HR, Rueda OM, Chin SF, Curtis C, Dunning M, Aparicio S and Caldas C. Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome Biology 15(8), 2014. 

2013

2012

    Yuan, Y, Failmezger H, Rueda OM, Ali R, Gräf S, Schwarz R, Chin SF, Curtis C, Bardwell H, Provenzano E, Aparicio S, Caldas C & Markowetz F. Quantitative image analysis of cellular heterogeneity in breast tumors. Science Translational Medicine, 4(157):157ra143, 2012. 

    Lynch AG, Chin SF, Dunning MJ, Caldas C, Tavaré S & Curtis C. Calling sample mixups in cancer population studies. PLoS One, 7(8): e41815, 2012. 

    Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, METABRIC Group, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Børrensen-Dale, Brenton JD, Tavaré, Caldas C & Aparicio S. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature, 486(7403):346-52, 2012. 

    Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, Griffith M, Moradian A, Cheng SW, Morin GB, Watson P, Gelmon K, Chia S, Chin SF, Curtis C, Rueda OM, Pharoah PD, Damaraju S, Mackey J, Hoon K, Harkins T,Tadigotla V, Sigaroudinia M, Gascard P, Tlsty T, Costello JF, Meyer IM, Eaves CJ, Wasserman WW, Jones S, Huntsman D, Hirst M, Caldas C, Marra MA, Aparicio S. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature, 486(7403):395-9, 2012. 

    Maia AT, Antoniou AC, O'Reilly M, Samarajiwa S, Dunning M, Kartsonaki C, Chin SF, Curtis C, McGuffog L, Domchek SM, Embrace E, Easton DF, Peock S, Frost D, Evans DG, Eeles R, Izatt L, Adlard J, Eccles D, Gemo G, Sinilnikova OM, Mazoyer S, Stoppa-Lyonnet D, Gauthier-Villars M, Faivre L, Venat-Bouvet L, Delnatte C, Nevanlinna H, Couch FJ, Godwin AK, Caligo MA, Swe-Brca SB, Barkardottir RB, Kconfab K, Chen X, Beesley J, Healey S, Caldas C, Chenevix-Trench G, Ponder BA. Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. Breast Cancer Res, 18;14(2):R63, 2012. 

2011 & Earlier